Naarden, The Netherlands – June 9, 2025 – Forbion, a leading venture capital firm with deep biotech expertise in Europe and the US announces that it has co-led an $80 Million Series A financing in Mosanna Therapeutics, a biotech company rethinking treatment of obstructive sleep apnea (OSA). The company is developing an easy-to-use nighttime nasal spray to treat obstructive sleep apnea that will help restore the body’s natural airway control. The financing was led by Pivotal bioVenture Partners and EQT Life Sciences, along with Forbion, Broadview Ventures and Norwest as co-lead investors. Returning investors included founding investor Forty51 Ventures, as well as Supermoon Capital and High-Tech Gründerfonds (HTGF).
OSA is the most common sleep-related breathing disorder, affecting an estimated 1 billion people globally. Left untreated, OSA is linked to serious health risks including hypertension, cardiovascular disease, stroke, depression and excessive daytime sleepiness – contributing to workplace and car accidents. Despite OSA’s prevalence, treatment has largely focused on mechanical solutions that are often uncomfortable and disruptive.
Mosanna is pioneering a pharmaceutical solution for sleep apnea patients with MOS118, a nasal spray administered at bedtime that helps restore the body’s natural airway reflex. MOS118 targets the upper airway muscles that are responsible for maintaining airway patency. Research has shown that, for reasons yet unknown, the natural airway reflex in OSA patients exhibits decreased activity during sleep resulting in loss of airway patency and apnea. The new funding will support the advancement of MOS118 through Phase 2 development while also supporting expansion of Mosanna’s pipeline.
What sets Mosanna apart is its fundamentally different approach to sleep apnea, treating it as a muscular dysfunction rather than a purely mechanical issue. MOS118 is the first therapy we have seen that restores the body’s natural airway reflex with the simplicity of a nasal spray. This has the potential to dramatically improve adherence and outcomes in a patient population that has long been underserved. At Forbion, we are focused on supporting bold science that addresses clear medical needs, and we believe Mosanna’s innovation could redefine the standard of care for obstructive sleep apnea.
Dmitrij Hristodorov
PhD., General Partner at Forbion
Mosanna also appointed veteran biotech leader David Weber, Ph.D., as President and Chief Executive Officer to guide Mosanna’s next stage of growth. With more than 30 years of experience spanning drug development, capital formation and corporate strategy, Dr. Weber has led teams across both public and private life sciences companies. Dr. Weber was also appointed to Mosanna’s Board of Directors.
“Mosanna is taking a truly transformational approach to sleep apnea treatment – offering a non-invasive, non-mechanical solution designed to seamlessly fit into daily life,” said Dr. Weber. “No one has sleep apnea while awake, because our bodies instinctively keep the airway open. Mosanna simply helps to restore this natural reflex during sleep – delivering a nasal spray alternative to invasive mechanical workarounds. With this funding, we’re accelerating development to bring this groundbreaking treatment to patients who desperately need better options."
